We found that EXO1 promoted BCL2, CDC25, and PCNA and inhibited BAX expression (Additional file 5: Fig. S5A–I), and further experiments showed that EXO1 inhibited apoptosis in prostate cancer cells. Here, BCL2 is linked to prostate cancer.